Arterial Remodeling Technologies (‘ART’) signs structured buyout agreement with Terumo, validating ART’s next-gen

  Arterial Remodeling Technologies (‘ART’) signs structured buyout agreement
  with Terumo, validating ART’s next-gen bioresorbable scaffold

Terumo Corporation obtains an exclusive option to purchase ART’s bioresorbable
   scaffold technology for use in the treatment of coronary artery disease

Business Wire

PARIS -- March 27, 2014

Privately held Arterial Remodeling Technologies (‘ART’) announced today that
it has signed a structured buyout agreement with Terumo Corporation. Under the
agreement, ART and Terumo Corporation will collaborate in the development of a
drug eluting bioresorbable scaffold or stent, intended for use in the
treatment of coronary artery disease. ART Security Holders will retain full
ownership of the ART bioresorbable scaffold technology for all other
indications. Terumo Corporation will make staged R&D investments in ART and
ART has granted an exclusive option to Terumo Corporation to purchase ART at
any time prior to the initiation of clinical trials.

ART’s advanced bioresorbable scaffold is designed to provide a transient
effective scaffold that dismantles and relinquishes its primary mechanical
scaffolding function after three months, which is commonly recognized by
experts as the requisite length of time necessary to allow the healing process
to stabilize the artery following trauma generated by angioplasty, and to
avoid recoil and constrictive remodeling.

“We are proud of consummating an agreement with Terumo Corporation, one of the
leading medical technology companies in the world,” said Machiel van der
Leest, CEO, and a Director of ART. “Terumo Corporation understands the value
of our bioresorbable scaffold. The scaffold is designed to perform as
effectively as a conventional metallic stent, but with the significant
advantage of relinquishing its scaffolding function when the stent is no
longer necessary to maintain the vessel.”

“We are, of course, extremely pleased with this agreement,” said Eric Viaud,
Chairman of the Board of ART. “It validates the vision the board shared with
the late Beatrice Denys, who was a partner at SEFTI investments. Beatrice
identified early on the unique idea of co-founders Pr. Antoine Lafont and Pr.
Michel Vert.”

ART wishes to thank its investors: Bpifrance (www.bpifrance.fr), Idinvest
Partners (www.idinvest.com), Turenne Capital Partners
(www.turennecapital.com), Matignon Investissement & Gestion
(www.matinvest.com), Vesale Partners and Amundi Asset Management
(www.amundi.com).

ART also wishes to thank three esteemed institutions for their invaluable
support: the Cleveland Clinic; the French national research institute, CNRS,
Montpellier, France; and, Descartes University, Paris.

About Arterial Remodeling Technologies (“ART”)

Arterial Remodeling Technologies (“ART”) is developing bioresorbable polymer
stents that promote the natural remodeling of an injured artery after
angioplasty. The Company’s technology is based on intellectual property
originating from three esteemed institutions: the Cleveland Clinic; the French
national research institute, CNRS (Centre National de Recherche Scientifique),
Montpellier, France; and, Descartes University, Paris.

CAUTION: ART’s bioresborbable stent is not approved for investigational use or
sale in the U.S.

Contact:

Ronald Trahan Associates Inc.
Ronald Trahan, 508-359-4005, x108
APR
 
Press spacebar to pause and continue. Press esc to stop.